Inside the KLOW Stack: The Four Peptides

The short version

The KLOW stack is a research vial containing four separate peptides at fixed mass ratios: GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg) and KPV (10 mg) — total 80 mg. They do not form a single new compound. Each is a chemically distinct molecule with its own structure, mechanism and research record.

GHK-Cu is a copper-carrying tripeptide studied for collagen production and broad gene-expression effects. BPC-157 is a 15-amino-acid peptide studied in animal tendon and tissue-repair models. TB-500 is a short actin-binding heptapeptide fragment derived from thymosin beta-4, a protein with a documented role in wound re-epithelialization and cell migration. KPV is an anti-inflammatory tripeptide that is absorbed through a specific gut transporter and suppresses inflammatory gene activity.

No controlled study has tested the combination. This page opens each constituent individually — structure, mechanism, the studies, and where the evidence runs out. The gap where a combination study would sit is left visible.

KPV: the anti-inflammatory arm

KPV (Lysine-Proline-Valine, CAS 67727-97-3, MW 342.44 Da) is the C-terminal three-amino-acid fragment (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). The sequence is L-Lys-L-Pro-L-Val. It is the smallest component of the canonical vial at 10 mg.

Mechanism: KPV is a substrate of the PepT1 di/tripeptide transporter (SLC15A1, Km approximately 160 micromolar) expressed in intestinal epithelium and macrophages — a transporter that is upregulated when the gut is inflamed, giving KPV a route into precisely the tissue where its anti-inflammatory activity is most relevant ^[3]. Inside those cells, nanomolar KPV inhibits NF-kappaB p65/RelA nuclear import (NF-kappaB is the master transcription factor that turns inflammatory genes on) and suppresses MAP-kinase signaling, reducing production of TNF-alpha, IL-6, IL-1beta and IL-8 ^[3].

Studies: in human intestinal epithelial cell lines and Jurkat T cells in vitro, nanomolar KPV reduced NF-kappaB and MAPK activation. In DSS- and TNBS-induced colitis (chemically induced inflammatory bowel disease) in C57BL/6 mice, oral KPV in drinking water at 100 micromolar reduced disease severity ^[3].

Human data: restricted to early delivery pilots; no controlled monotherapy trial has reached approval.

Role in KLOW: the immune-resolution and gut-selective anti-inflammatory arm. Its immunomodulatory activity is a theoretical variable in active infections and autoimmune disease — a caution detailed on the KLOW effects page.

GHK-Cu: the matrix and copper arm

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper(II) complex, Copper Tripeptide-1, CAS 89030-95-5, MW 402.92 Da) is the mass-dominant component at 50 mg of the 80 mg total — approximately 62.5% of the vial by mass. First isolated from human plasma by Loren Pickart in 1973, its endogenous plasma levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[4].

Mechanism: GHK-Cu delivers a chelated copper(II) ion to tissues. Copper is essential for lysyl oxidase (an enzyme that crosslinks collagen and elastin fibers, giving connective tissue its strength) and for other enzymes in the antioxidant and matrix pathways. Beyond copper delivery, GHK modulates gene expression at remarkable breadth: a 2018 bioinformatic analysis found it shifts expression of approximately 31% of human protein-coding genes at a 50%-or-greater threshold, with the strongest signals on matrix synthesis, antioxidant defense, DNA repair and protein quality control ^[5].

Studies: a 2015 review established multi-modal matrix synthesis effects and documented placebo-controlled improvements in skin laxity, fine lines and wrinkle depth ^[4]. A 2016 controlled human trial showed a GHK-containing topical (ALAVAX) increased hair count by 52.6-71.5 versus 9.6 for placebo (p<0.05) over six months in 45 men with pattern hair loss ^[8]. GHK-Cu liposomes accelerated murine scald-wound healing and increased endothelial cell proliferation by 33.1% versus controls, upregulating VEGF and FGF-2 ^[10].

Role in KLOW: the primary matrix-remodeling, collagen-synthesis and antioxidant-defense arm. The copper load this component carries is a mechanistic consideration for individuals with copper-handling disorders (e.g. Wilson's disease) — see the KLOW effects page.

Note: the KLOW vial carries approximately 50 mg of GHK-Cu — a large copper delivery. Co-dissolving GHK-Cu with three other peptides in one vial raises a theoretical compatibility concern (copper can participate in redox chemistry) that has not been formally characterized for this mixture.

BPC-157: the angiogenic arm

BPC-157 (Body Protection Compound 157, PL 14736, CAS 137525-51-0, MW 1419.53 Da) is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a protein identified in human gastric juice. Originally developed as PL 14736 for inflammatory bowel disease.

Mechanism: BPC-157 activates VEGFR2/PI3K/Akt/eNOS signaling — the primary pathway for angiogenesis (new blood vessel formation). It upregulates the growth-hormone receptor in tendon fibroblasts, modulates the nitric-oxide system in a manner partly resistant to L-NAME, and promotes formation of new vasculature in ischemic tissue. Its 503A regulatory status: the FDA placed BPC-157 in category 2 of the 503A bulk-substances review.

Studies: BPC-157 accelerated healing of fully transected rat Achilles tendons across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in vitro at doses from 10 micrograms to 10 picograms per rat ^[2]. A 2025 Sikiric review placed it in a broader safety and counter-intoxication pharmacology context ^[12]. The human evidence: a 2025 first-in-human intravenous safety pilot dosed two adults at up to 20 mg IV; no adverse events and no safety-biomarker changes were observed ^[6].

Role in KLOW: the angiogenesis and tissue-vascularization arm. Its pro-angiogenic mechanism is a theoretical consideration in active cancer — see the KLOW effects page.

TB-500: the cytoskeletal arm

TB-500 is the synthetic N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTET-Q, MW 889.02 Da), corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). This distinction is load-bearing: most of the foundational efficacy data in the wound-closure, angiogenesis and hair-follicle literatures are for full-length native thymosin beta-4, not for the TB-500 heptapeptide fragment.

Mechanism: the LKKTET motif sequesters G-actin (monomeric actin) by binding it 1:1 — a mechanism confirmed by 2-angstrom X-ray crystallography ^[11]. Sequestering actin monomers keeps them in reserve and regulates the local actin pool available for cell migration. Full-length thymosin beta-4 additionally activates integrin-linked kinase and mobilizes epicardial progenitor cells — activities established for the native protein, not demonstrated for the TB-500 fragment.

Studies: full-length thymosin beta-4 increased re-epithelialization 42% at four days and 61% at seven days in rat full-thickness wound models ^[1], promoted angiogenesis, wound healing and hair follicle development in a multi-endpoint rodent study ^[9], activated hair-follicle bulge stem cells and increased MMP-2 (a matrix-remodeling enzyme) expression ^[12], and in 2025 was shown to work through specialized pro-resolving pathways ^[13]. A 2025 Tbeta4-exosome hydrogel study demonstrated enhanced vascularized wound healing ^[14].

WADA status: thymosin beta-4 / TB-500 is listed on the WADA Prohibited List under S2 (peptide hormones and growth factors), banned at all times in and out of competition. Because TB-500 is a constituent of the KLOW blend, the full blend implicates anti-doping rules in any athletic-research context ^[7].

Role in KLOW: the cytoskeletal cell-migration and wound-epithelialization arm.

The combination: what is and is not known

Four constituents. Four separate lights. One vial. And the region that does not glow.

The combination rationale — that KPV resolves inflammation, GHK-Cu rebuilds the matrix, BPC-157 drives angiogenesis and TB-500 accelerates cell migration — is mechanistically coherent. These are four non-overlapping nodes of one tissue-repair signaling cascade.

What does not exist: any controlled study of the KLOW blend against monotherapy, any subset, or placebo. No pharmacokinetic study of the co-formulated vial. No human efficacy data. No safety characterization of the combination.

The pharmacokinetic mismatch is inherent: the tripeptides KPV and GHK-Cu clear far faster than BPC-157, and the TB-500 fragment has different kinetics from native thymosin beta-4. A single co-formulated dose cannot maintain all four constituents at matched exposures.

This is the dispensary's honest record: four lit components, one region kept dark because the light of a combination trial has not yet been struck.